Programmed cell death protein 1 (PD-1)/Programmed cell death protein ligand 1 (PD-L1) mAbs abrogate the inhibitory interaction between PD-L1 expressed by tumor cells and immunosuppressive cells in the tumor microenvironment and PD-1 expressed by effector T-cells, thereby enhancing the effector T-cell’s antineoplastic activity [4]. This evidence concerns the gene PDCD1 and neoplasm.